News
AKYA
2.460
+0.82%
0.020
U.S. RESEARCH ROUNDUP-Colgate-Palmolive, McKesson, Microsoft
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Colgate-Palmolive, McKesson, Microsoft and Air Products & Chemicals among those. AIG, AIG and others have seen their target prices cut by some analysts.
Reuters · 3d ago
AKOYA BIOSCIENCES INC <AKYA.O>: STEPHENS CUTS TARGET PRICE TO $4.50 FROM $6
Reuters · 3d ago
Weekly Report: what happened at AKYA last week (0715-0719)?
Weekly Report · 4d ago
Akoya Biosciences: Poised for Recovery and Growth Amidst Market Challenges
TipRanks · 07/17 16:26
Weekly Report: what happened at AKYA last week (0708-0712)?
Weekly Report · 07/15 09:00
Weekly Report: what happened at AKYA last week (0701-0705)?
Weekly Report · 07/08 09:00
Weekly Report: what happened at AKYA last week (0624-0628)?
Weekly Report · 07/01 09:01
Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost
Akoya Biosciences, Inc. Share price has bounced 31% in the last month. The company's price-to-sales ratio of 1.4x is lower than most other companies in the Life Sciences industry. Its forecasted revenue growth is higher than the rest of its industry. However, the company's P/S might be low for a reason.
Simply Wall St · 06/27 10:18
Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?
Akoya Biosciences, Inc. (NASDAQ:AKYA) has US$75.5m of debt on its balance sheet. The company is using debt to fund its operations, but is this a concern for shareholders? Debt is a sign of a company's ability to pay off its debts. Akoya B biosciences burned through US$56m of cash in the last year. We've discovered 3 warning signs for Akoya bioscience that you should be aware of.
Simply Wall St · 06/24 19:52
Akoya Biosciences: Poised for Growth in Spatial Biology and Precision Medicine
TipRanks · 06/24 10:56
Weekly Report: what happened at AKYA last week (0617-0621)?
Weekly Report · 06/24 09:01
BUZZ-Akoya Biosciences up after Craig-Hallum starts with 'buy' rating
Brokerage Craig-Hallum starts coverage on medtech firm Akoya Biosciences with 'buy' rating and $7.50 price target. Shares of Akoya rise 8% to $2.41. Stock down 50% YTD. Company has potential to be a $500 million revenue company in five years.
Reuters · 06/21 15:43
AKOYA BIOSCIENCES, INC. <AKYA.O> : CRAIG-HALLUM INITIATES COVERAGE WITH BUY RATING AND TARGET PRICE $7.5
Reuters · 06/21 11:20
Weekly Report: what happened at AKYA last week (0610-0614)?
Weekly Report · 06/17 09:00
Weekly Report: what happened at AKYA last week (0603-0607)?
Weekly Report · 06/10 09:01
Analyst Scoreboard: 4 Ratings For Akoya Biosciences
Akoya Biosciences (NASDAQ:AKYA) is a life sciences technology company. The company has a 12-month price target of $6.5. It has been downgraded by 4 analysts in the past three months. The firm's revenue growth lags behind its peers in the health care sector.
Benzinga · 06/03 14:00
Akoya Biosciences Is Maintained at Overweight by Morgan Stanley
Dow Jones · 06/03 13:15
Akoya Biosciences Price Target Cut to $4.00/Share From $8.00 by Morgan Stanley
Dow Jones · 06/03 13:15
Morgan Stanley Maintains Overweight on Akoya Biosciences, Lowers Price Target to $4
Benzinga · 06/03 13:05
Weekly Report: what happened at AKYA last week (0527-0531)?
Weekly Report · 06/03 09:01
More
Webull provides a variety of real-time AKYA stock news. You can receive the latest news about Akoya Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AKYA
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).